Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Multiple myeloma - bortezomib (induction therapy): evaluation report

01.   Pre-Meeting Briefing prepared by NICE

02.   Submission from the technology manufacturer – Janssen

03.   NICE request to the Manufacturer for clarification on their submission

04.   Manufacturer clarification response

05.   Consultee submission – Myeloma UK

06.   Consultee submission – Royal College of Physicians

07.   Consultee submission – UK Myeloma Forum endorsed by Royal College of Pathologists & The British Society for Haematology

08.   Clinical expert personal perspective – Bird

09.   Clinical expert personal perspective – Yong

10.   Patient expert personal perspective – Low

11.   Patient expert personal perspective – Fullerton

12.   Evidence Review Group report prepared by – SHTAC

13.   Manufacturer factual accuracy check of the Evidence Review Group report

14.   Erratum to the Evidence Review Group report prepared by – SHTAC

15.   Addendum to the manufacturer submission – Janssen

16.   Addendum to the Evidence Review Group report prepared by – SHTAC

17.   Evidence Review Group – Exploratory analysis